 BeyondSpring Inc. the Company or BeyondSpring BYSI, a New York-based global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that, following discussions with the U.S. Food and Drug Administration FDA, the Company has formally changed the primary endpoint for its Study 106 Phase 3 superiority clinical trial with first-in-class lead asset, Plinabulin, for chemotherapy-induced neutropenia CIN prevention. For more than 20 years, the standard primary endpoint for CIN trials has been the duration of severe Grade 4 neutropenia DSN. 